glp-1 treatment for newly diagnosed diabetes guidelines The management of type 1 in adults. A consensus report by the American Diabetes Association (ADA) and the European Association the Study of Diabetes (EASD) The new Diabetes mellitus guidelines

SURPASS-CVOT is a phase 3 study enrolled approximately 13,000 patients at least 40 years of age and have a diagnosis of type 2 diabetes, confirmed atherosclerotic cardiovascular disease, HbA1c 7.0% to 10.5% and a body mass index (BMI) 25 kilograms per meter squared (kg/m 2 )

Another trial demonstrated a significant reduction in body weight with the use of semaglutide, with subjects losing up to 14.9% of their initial body weight over a period of 68 weeks

If approved, orforglipron would be the first oral GLP-1 receptor agonist approved for weight loss

N., & Klise, S

Wharton S, Batterham RL, Bhatta M, et al

Future Pipeline: Multiple pharmaceutical companies are developing next-generation weight loss medications, including: Oral GLP-1 formulations Triple agonist medications (GIP/GLP-1/glucagon) Long-acting formulations (monthly injections) Understanding the best GLP-1 weight loss programs helps you access these highly effective medications affordably